Drug-Target Interaction (DTI) Prediction is the computational task of predicting whether and how strongly a drug molecule binds to a protein target — modeling the molecular recognition event where a small molecule (ligand) fits into a protein's binding pocket through complementary shape, charge, and hydrophobic interactions, enabling virtual identification of drug-target pairs from the combinatorial space of all possible molecule-protein combinations.

What Is DTI Prediction?

• Definition: Given a drug molecule $D$ (represented as a molecular graph, SMILES string, or 3D conformer) and a protein target $T$ (represented as an amino acid sequence, 3D structure, or binding pocket), DTI prediction estimates either a binary interaction label ($y in {0, 1}$: binds or does not bind) or a continuous binding affinity ($y in mathbb{R}$: $K_d$, $K_i$, or $IC_{50}$ value). The task models the biophysical lock-and-key mechanism computationally.
• Input Representations: (1) Drug: molecular graph (GNN encoder), SMILES string (Transformer encoder), or 3D conformer (equivariant GNN). (2) Target: amino acid sequence (protein language model — ESM, ProtTrans), 3D structure (geometric GNN on protein graph), or binding pocket (voxelized 3D grid or point cloud). The choice of representation determines what molecular recognition signals the model can capture.
• Cross-Attention Mechanism: Modern DTI models use cross-attention between drug atom representations and protein residue representations — drug atom $i$ attends to protein residues to identify which pocket residues it interacts with, and protein residue $j$ attends to drug atoms to identify which ligand features complement its binding properties. This bilateral attention discovers the intermolecular contacts that drive binding.

Why DTI Prediction Matters

• Drug Repurposing: Predicting new targets for existing approved drugs (drug repurposing/repositioning) is the fastest path to new treatments — the drug is already proven safe in humans. DTI prediction can screen a database of ~3,000 approved drugs against ~20,000 human protein targets ($6 imes 10^7$ pairs), identifying unexpected drug-target interactions that suggest new therapeutic applications.
• Polypharmacology: Most drugs bind multiple targets (polypharmacology), not just the intended one. Off-target binding causes side effects — predicting all targets a drug binds enables anticipation of adverse effects and rational design of multi-target drugs (designed polypharmacology) that simultaneously modulate multiple disease-related targets.
• Virtual Screening Pre-Filter: Before running expensive physics-based molecular docking ($sim$seconds/molecule), a DTI classifier provides a fast pre-filter ($sim$microseconds/molecule) that eliminates molecules with low predicted interaction probability, reducing the docking candidate pool from billions to thousands and making structure-based virtual screening computationally feasible.
• Protein-Ligand Co-Folding: The latest DTI approaches (AlphaFold3, RoseTTAFold All-Atom) jointly predict the protein structure and ligand binding pose — given only the protein sequence and the ligand SMILES, they predict the 3D complex structure, implicitly solving DTI prediction as a structure prediction problem.

DTI Prediction Approaches

Drug-Target Interaction Prediction is molecular matchmaking — computationally evaluating which molecular keys fit which protein locks across the vast combinatorial space of drug-target pairs, enabling drug repurposing, side effect prediction, and efficient virtual screening at a scale impossible for experimental methods.